We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+12.31%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.4B
AUM Growth
-$103M
Cap. Flow
-$192M
Cap. Flow %
-13.74%
Top 10 Hldgs %
58.28%
Holding
52
New
10
Increased
7
Reduced
7
Closed
17

Top Buys

Rank Stock Value
1
CYBX
CYBERONICS INC
CYBX
+$45.7M
2
ABBV icon
AbbVie
ABBV
+$45.3M
3
SEM
Select Medical
SEM
+$41.6M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$34.9M
5
MDCO
Medicines Co
MDCO
+$33.1M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$74.8M
2
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$45.6M
3
VTRS icon
Viatris
VTRS
+$42.3M
4
CNMD icon
CONMED
CNMD
+$35M
5
BSX icon
Boston Scientific
BSX
+$33.1M

Sector Composition

Rank Sector Weight
1 Healthcare 62.03%
2 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPCH icon
26
Option Care Health
OPCH
$3.45B
$13.3M 0.95%
+750,000
New +$16.4M
ANGO icon
27
AngioDynamics
ANGO
$611M
$13M 0.93%
728,483
+363,853
+100% +$6.76M
MDRX
28
DELISTED
Veradigm Inc. Common Stock
MDRX
$12M 0.85%
+1,000,000
New +$12.2M
BIOL
29
DELISTED
Biolase, Inc.
BIOL
$11.3M 0.81%
591
+147
+33% +$4.16M
PLX icon
30
Protalix BioTherapeutics
PLX
$191M
– –
-200,000
Closed -$3.92M
NVTA
31
DELISTED
Invitae Corporation
NVTA
$6.7M 0.48%
+400,000
New +$7.41M
OSUR icon
32
OraSure Technologies
OSUR
$279M
$5.65M 0.4%
+864,223
New +$7.18M
CRDC
33
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$5.27M 0.38%
837,485
– –
GYRE icon
34
Gyre Therapeutics
GYRE
$641M
$4.63M 0.33%
1,981
– –
INO icon
35
Inovio Pharmaceuticals
INO
$55.7M
$2.04M 0.15%
20,833
– –
BSX icon
36
Boston Scientific
BSX
$69.5B
– –
-2,500,000
Closed -$33.1M
DGX icon
37
Quest Diagnostics
DGX
$25.7B
– –
-197,622
Closed -$13.3M
GSK icon
38
CALL
GSK
GSK
$104B
– –
-800,000
Closed -$42.7M
GSK icon
39
GSK
GSK
$104B
– –
-1,400,000
Closed -$74.8M
NVAX icon
40
Novavax
NVAX
$1.2B
– –
-100,000
Closed -$11.9M
PTCT icon
41
PTC Therapeutics
PTCT
$5.68B
– –
-525,000
Closed -$27.2M
TEVA icon
42
CALL
Teva Pharmaceuticals
TEVA
$40.8B
– –
-500,000
Closed -$28.8M
VTRS icon
43
Viatris
VTRS
$20.4B
– –
-750,000
Closed -$42.3M
WW
44
DELISTED
WW International
WW
– –
-1,146,741
Closed -$28.5M
EGRX
45
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-200,400
Closed -$3.11M
BIOL
46
CALL
DELISTED
Biolase, Inc.
BIOL
– –
-147
Closed -$139K
PFNX
47
CALL
DELISTED
Pfenex Inc.
PFNX
– –
-1,000,000
Closed -$31.1M
ALR
48
DELISTED
Alere Inc
ALR
– –
-500,000
Closed -$19M
AFFX
49
DELISTED
Affymetrix Inc
AFFX
– –
-1,000,000
Closed -$9.87M
BRLI
50
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
– –
-11,485
Closed -$369K
1
2
3

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Camber Capital Management held 52 positions worth $1.4B, down 6.9% from $1.5B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Camber Capital Management withdrew a net $192M in Q1 2015, closing 17 positions and reducing 7 holdings. Its most notable exit was GSK, an estimated $74.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 59% a quarter earlier, followed by Consumer Discretionary.

Against the trend, Camber Capital Management opened a new position in CYBERONICS INC worth $48.7M.

  • Camber Capital Management's largest Q1 2015 buy was CYBERONICS INC: 750,000 shares worth $48.7M.
  • Camber Capital Management added most to Medicines Co in Q1 2015, an estimated $33.1M increase.
  • Camber Capital Management's biggest Q1 2015 reduction was CONMED, cutting an estimated $35M.
  • Camber Capital Management fully exited GSK in Q1 2015, selling an estimated $74.8M.
  • Camber Capital Management's ten largest holdings make up 58% of its $1.4B portfolio in Q1 2015.
  • Camber Capital Management opened 10 new positions and closed 17 in Q1 2015.
  • Camber Capital Management's portfolio value fell 6.9% quarter-over-quarter to $1.4B.

Based on Camber Capital Management's 13F filing for Q1 2015, filed 15 May 2015.